Navigation Links
Positive results for airway bypass
Date:10/9/2007

Mountain View, CA, October 9, 2007 - Broncus Technologies, Inc., a medical device company investigating the airway bypass procedure for the treatment of emphysema, today announced that the results of its open-label Exhale Drug-Eluting Stent feasibility study have been published in the October issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results include a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure.

Airway bypass is a catheter-based bronchoscopic procedure designed to reduce lung hyperinflation and improve breathlessness (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs. During the minimally invasive procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by Exhale Drug-Eluting Stents. The hope is to improve quality of life by relieving severe symptoms including shortness of breath and hyperinflation of the chest.

Emphysema, a component of COPD, is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving emphysema sufferers with hyperinflation because they are unable to get air out of their lungs. Breathing becomes inefficient and patients have to work very hard just to breathe making normal activities, like walking, eating or even bathing, difficult. Treatment options for most patients with emphysema are currently limited and generally result in anguished patients and frustrated physicians.

The prospectively-defined primary endpoint of this feasibility study was a reduction in residual volume (RV, the amount of air remaining in the lungs after full exha
'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies
Source:Eurekalert

Page: 1 2

Related biology news :

1. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
2. Insight into the processes of positive and negative learners
3. HIV-infected adults in Botswana respond positively to ARV therapy public treatment program
4. Malaria treatment efficacy compromised in certain HIV-positive patients
5. To slow AIDS in Russia, treat HIV-positive addicts, Stanford study says
6. Gene vaccine for Alzheimers disease shows promising results
7. Roche clinical trial registry and results database launched
8. Diabetic nerve therapy shows striking results
9. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
10. New results validating Pall prion reduction filter disclosed at ISBT Congress
11. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... plants ship sugars from their leaves to flowers, roots, ... engineering techniques, Cornell researchers have finally proven a long-standing ... deepen understanding of basic plant biology but could one ... photosynthetic rates, yields and carbon dioxide intake. This might ...
... to better understand the relationship between the bacteria ... defense cells that engulf them., The researchers have ... tuberculosis does not react when immune system ... bacterium,s genes become activated minutes after the pathogen ...
... winners of its student travel award to attend the ... Biophysics Congress in Long Beach, California, February 2-6, 2008. ... on scientific merit, with priority given to those who ... awardee receives a travel grant and will be recognized ...
Cached Biology News:Cornell researchers prove how plants transport sugars 2Cornell researcher seeks clues to how tuberculosis infects cells 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging ... vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ... clinical decisions with simultaneous access to high precision medical images and electronic health ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... equipment, to creating professional commercial video content, to analysis of athletic performance. Producing ... events that go by too quickly to process with the naked eye. ...
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , the leader in products ... Spirax Sarco Anytime. This platform, offering unique online ordering capabilities, is only available ... Log on to Spirax Sarco Anytime and within minutes you can be making ...
(Date:9/1/2015)... 2015 Prostate cancer is the second ... men. One in seven men will be diagnosed ... are diagnosed annually. That said, not every diagnosis ... new technique, MRI Fusion Biopsy, to more accurately ... only the affected areas and monitoring areas ...
Breaking Biology Technology:Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4
... 25 DSM,Biologics, a business unit of DSM Pharmaceutical Products, ... ; Swiss Exchange:,CRX), today announced that Hungary-based Gedeon Richter Plc. ... produce,certain biopharmaceuticals on the PER.C6(R) platform. , ... disclosed. , About PER.C6(R) ...
... clinical stage regenerative medicine company focused on the development of neo-organs ... Executive Officer of Tengion, will present at the Piper Jaffray 20th ... EST at The Palace Hotel in New York City, New York. ... , , Tengion, a clinical stage ...
... Nov. 25 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... and the three-month period ended September,30, 2008. The Company ... am eastern time (details follow below). , ... of $77.8 million,an increase of 18% from fiscal 2007 revenues ...
Cached Biology Technology:DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 2Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 3Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 4Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 5Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 6Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 7Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 8Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 9Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 10Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 11
XA7 B6...
... motor and ballscrew technologies, the ... solutions that include all the ... motors., , XY and ... high-flex cabling for power, signals, ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
...
Biology Products: